Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

CDC IXIS Innovation

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 6
Average round size
info
The average size of a deal this fund participated in
$87M
Portfolio companies 5
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 4
Key employees Soon
Paris, Ile-de-France, France
Stages of investment
Early Stage Venture

Areas of investment

  • Manufacturing
  • Medical
  • Biotechnology
  • Health Care
  • Consumer
Summary

The company was established in Europe in France. The main office of represented VC is situated in the Paris.

For fund there is a match between the location of its establishment and the land of its numerous investments - France. Among the most popular portfolio startups of the fund, we may highlight Kuros Biosciences, OneAccess, NEMOPTIC. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biopharma, Mobile.

Deals in the range of 5 - 10 millions dollars are the general things for fund. Opposing the other organizations, this CDC IXIS Innovation works on 21 percentage points more the average amount of lead investments. Considering the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2017. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2002.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the CDC IXIS Innovation, startups are often financed by Viventures Partners SA, Ventech, Eurazeo. The meaningful sponsors for the fund in investment in the same round are Auriga Partners, Viventures Partners SA, Venture Incubator, LLC. In the next rounds fund is usually obtained by Ventech, VI Partners AG, VINCI CAPITAL.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of CDC IXIS Innovation:
1 Eurazeo
2 Ventech
Typical Co-investors
CDC IXIS Innovation is more likely to invest in rounds together with the following funds:
1 Carmen Innovations
2 Stoneway Capital
3 WI Ventures, LLC
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after CDC IXIS Innovation:
1 Avathon Capital
2 Daiwa Food & Agriculture
3 Genesis Ark

Funds with similar focus

Funds from France
Funds with similar focus located in France:
1 C4 Ventures
2 Galia Gestion
3 Sigma Gestion
4 Truffle Capital
5 Turenne Capital
Funds with the same geo focus
Funds with similar geography of portfolio companies:
1 4FO Ventures
2 BlueOcean Ventures
3 Equitypitcher
4 GoBeyond
5 Technology Fund
Funds doing lead investments
Funds with similar focus acting as lead investors:
1 3D Investment Partners
2 Althea Partners
3 Catalys Pacific
4 China Resources Pharmaceutical Industry Investment Fund
5 Plains Venture Partners
Look at other 50 related and similar funds Collapse list ↓
Fund NameLocation
Baxalta Ventures Cambridge, Massachusetts, United States
BioVeda China Fund China, Shanghai
CoFound Partners New York, New York, United States
Huigu Chuang Tou Changning, China, Shanghai
Innogenetics Belgium, Gent, Oost-Vlaanderen
Kodak New York, Rochester, United States
London School of Economics and Political Science (LSE) England, London, United Kingdom
Matrix Herzliya, Israel, Tel Aviv
MFI Capital Austin, Texas, United States
Ogaki Kyoritsu Bank Gifu Prefecture, Japan, Ogaki
Padup Ventures Gurgaon, Haryana, India
Shigin Economic Research Institute -
Starstrike Ventures Berlin, Berlin, Germany
Startupbootcamp Digital Health Chengdu Chengdu, China, Sichuan
Treasury New York, New York, United States
UAE Exchange Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Upfront Ventures Community Fund California, Los Angeles, United States
Vanderbilt University Nashville, Tennessee, United States
WuXi AppTec China, Shanghai, Shanghai
Yidou Investment China, Guangdong, Shenzhen

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

OneAccess

Manufacturing
Public Relations
Virtual Reality
$8M08 Jul 2004
Idinvest Partners
Viventures Partners SA
CM-CIC Capital Prive
CDC IXIS Innovation
 France, Ile-de-France, France

NEMOPTIC

Consumer
Manufacturing
Mobile
$12M05 Mar 2003
Alven Capital
Ventech
CDC IXIS Innovation
Auriga Partners
 Paris, Ile-de-France, France

Kuros Biosciences

Biopharma
Biotechnology
Health Care
Medical
$8M05 Nov 2002
CDC IXIS Innovation
Innovation Capital
Venture Incubator, LLC
 Zurich, Switzerland

NEMOPTIC

Consumer
Manufacturing
Mobile
$2M05 Aug 1999
CDC IXIS Innovation
Auriga Partners
 Ile-de-France
By posting comments on our website you confirm and acknowledge that:

1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.

2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.

3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.

4. We can moderate comments at any time.

5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.

6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.

Agree

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent CDC IXIS Innovation?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 6
Average round size 87M
Peak activity year 2002
Lead investments 1
Follow on index 0.17
Exits 4
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

OneAccess

Manufacturing
Public Relations
Virtual Reality
$8M08 Jul 2004
Idinvest Partners
Viventures Partners SA
CM-CIC Capital Prive
CDC IXIS Innovation
 France, Ile-de-France, France

NEMOPTIC

Consumer
Manufacturing
Mobile
$12M05 Mar 2003
Alven Capital
Ventech
CDC IXIS Innovation
Auriga Partners
 Paris, Ile-de-France, France

Kuros Biosciences

Biopharma
Biotechnology
Health Care
Medical
$8M05 Nov 2002
CDC IXIS Innovation
Innovation Capital
Venture Incubator, LLC
 Zurich, Switzerland

NEMOPTIC

Consumer
Manufacturing
Mobile
$2M05 Aug 1999
CDC IXIS Innovation
Auriga Partners
 Ile-de-France
Crunchbase icon

Content report

The following text will be sent to our editors:

Send